Question 1

What is GLOFITAMAB used for?

Accepted Answer

GLOFITAMAB (brand name Columvi) is a Other indicated for 1 INDICATIONS AND USAGE COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma.

Question 2

How does GLOFITAMAB work?

Accepted Answer

GLOFITAMAB works through the following mechanism: 12.1 Mechanism of Action Glofitamab-gxbm is a bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 receptor expressed on the surface of T cells. Glofitamab-gxbm causes T-cell activation and proliferation, secretion of cytokines, and the lysis of CD20-expressing B cells. Glofitamab-gxbm showed anti-tumor activity in vivo in mouse models of DLBCL..

Question 3

What are the most common side effects of GLOFITAMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for GLOFITAMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is GLOFITAMAB the same as Columvi?

Accepted Answer

Columvi is a brand name for GLOFITAMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

GLOFITAMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations